TORONTO–(BUSINESS WIRE)–Alcon, the global leader in eye care, announces the launch of Systane® PRO Preservative-Free (PF) in Canada.
Author: Business Wire
Voici SystaneMD PRO SANS AGENT DE CONSERVATION : la formule à triple action la plus durable d’Alcon pour jusqu’à 12 heures de soulagement des symptômes de la sécheresse oculaire
TORONTO–(BUSINESS WIRE)–Alcon, chef de file mondial des soins oculaires, qui se consacre à aider les gens à voir avec clarté, a annoncé aujourd’hui le lancement de SystaneMD PRO SANS AGENT DE CONSERVATION au Canada comme la formule la plus avancée de…
Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
TORONTO–(BUSINESS WIRE)–Alcon, the global leader in eye care, announces the launch of Systane® PRO Preservative-Free (PF) in Canada.
EyeCare Partners Announces Sale of Optometry Business
ST. LOUIS–(BUSINESS WIRE)–EyeCare Partners LLC (“EyeCare Partners” or the “Company”), the nation’s leading provider of clinically integrated eye care, announced today that it has entered into an agreement for the sale of its optometry business to MyE…
MyEyeDr. To Acquire EyeCare Partners Optometry Division
VIENNA, Va.–(BUSINESS WIRE)–MyEyeDr., a leading provider of comprehensive eye care and eyewear solutions, announced today that it has entered into an agreement with EyeCare Partners to acquire its optometry division, consisting of over 300 offices, i…
Verbraucherumfrage von STAAR Surgical: 71 Prozent der Deutschen möchten auf Sehhilfen verzichten, kennen aber ihre Alternativen nicht
HAMBURG, Germany–(BUSINESS WIRE)–Die STAAR Surgical Company, weltweit führender Anbieter von phakischen Intraokularlinsen mit der EVO™-Produktfamilie implantierbarer Collamer®-Linsen (EVO ICL™) zur Sehkorrektur, hat die Ergebnisse ihrer globalen Verb…
Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa
EMERYVILLE, Calif.–(BUSINESS WIRE)–Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced that the first patient has been dosed in its ongoing Phase 1/2 clinical study eva…
Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa
EMERYVILLE, Calif.–(BUSINESS WIRE)–Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced that the first patient has been dosed in its ongoing Phase 1/2 clinical study eva…
Octant Announces First Patient Dosed in Phase 1b/2 Clinical Study of OCT-980 for the Treatment of Retinitis Pigmentosa
EMERYVILLE, Calif.–(BUSINESS WIRE)–Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced that the first patient has been dosed in its ongoing Phase 1/2 clinical study eva…
STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regul…
STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regul…
Sydnexis Announces FDA Advisory Committee Meeting Date to Review NDA for SYD-101 for Pediatric Progressive Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., a clinical-stage pharmaceutical company developing SYD-101, a novel low-dose atropine formulation for the treatment of pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Adm…
Ora Launches Clinical Intelligence Committee, Bringing Collective KOL Guidance to Ophthalmic Research
BOSTON–(BUSINESS WIRE)– #clinicalresearch–Ophthalmic CRO Ora launches Clinical Intelligence Committee, expert network helps innovators navigate complexity, bring therapies to patients faster
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of two…
Novai Publishes Study Supporting Use of DARC Imaging Technology to Identify Patients at Risk of Central Vision Loss From Macular Atrophy
READING, England–(BUSINESS WIRE)–Novai, a medtech company pioneering earlier detection and intervention for eye and brain diseases, today announced publication of a peer-reviewed study in Expert Review of Ophthalmology supporting its Detection of Apo…
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the l…
Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AdvancingScience–Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminat…
Onnuri Smile Eye Clinic’s Patented 1mm SMILE Pro Technology Highlights Safety and Rapid Recovery
SEOUL, South Korea–(BUSINESS WIRE)– #CataractSurgery–Onnuri Smile Eye Clinic, a South Korean ophthalmology clinic, announced its patented 1mm SMILE Pro technique for safer surgery and faster recovery.
Ramona Optics Raises $25 Million Series A to Transform Biomedical Research with Massively Parallel Microscopy
DURHAM, N.C.–(BUSINESS WIRE)–Ramona Optics, Inc. (“Ramona”), a leading biotools company advancing human health with massively parallel computational imaging that delivers unrivaled precision and scale to biopharma and biomedical customers, today anno…
Peer-Reviewed Multi-Center Study Links GreenMan's InSightVR to Greater Cataract Patient Understanding, Advanced-Technology IOL Selection and Expectation Alignment
WEST FARGO, N.D.–(BUSINESS WIRE)–GreenMan Vision, Inc. today announced the publication of a peer-reviewed, multi-center study evaluating InSightVR, a patient-specific VR platform that helps cataract patients experience simulated vision with different…